Abstract | OBJECTIVES: METHODS: A total of 256 elderly patients with AD were assigned to daily treatment with 1.0 mg of minodronate or a daily treatment with risedronate combined with daily 1000 IU ergocalciferol and 1200 mg elemental calcium, and followed up for 12 months. RESULTS: At baseline, patients of both groups showed low 25-hydroxyvitamin D with compensatory hyperparathyroidism. Non-vertebral fractures occurred in 5 patients in the minodronate group and 7 patients in the risedronate group (5 hip fractures; one fracture each at the distal forearm and pelvis). There was no difference in risk of hip fracture between the two groups (p=.70; odds ratio=0.8). CONCLUSIONS: The study medications were well tolerated with relatively few adverse events and were equivalent in reducing the risk of a fracture in elderly patients with AD.
|
Authors | Y Sato, Y Honda, J Iwamoto, N Amano |
Journal | Journal of musculoskeletal & neuronal interactions
(J Musculoskelet Neuronal Interact)
Vol. 13
Issue 3
Pg. 346-52
(Sep 2013)
ISSN: 1108-7161 [Print] Greece |
PMID | 23989256
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Retracted Publication)
|
Chemical References |
- Bone Density Conservation Agents
- Diphosphonates
- Imidazoles
- YM 529
- Risedronic Acid
- Etidronic Acid
|
Topics |
- Accidental Falls
- Aged
- Alzheimer Disease
(complications)
- Body Mass Index
- Bone Density
(drug effects)
- Bone Density Conservation Agents
(therapeutic use)
- Diphosphonates
(therapeutic use)
- Etidronic Acid
(analogs & derivatives, therapeutic use)
- Female
- Fractures, Bone
(prevention & control)
- Humans
- Imidazoles
(therapeutic use)
- Osteoporosis
(complications, drug therapy)
- Risedronic Acid
|